"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A1,US 2016/0175491 A1,157-818-238-425-485,2016-06-23,2016,US 201615055012 A,2016-02-26,US 201615055012 A;;US 201414250025 A;;US 201361810543 P,2013-04-10,Local Drug Delivery Devices and Methods for Treating Cancer,"Drug-eluting devices and methods for the treatment of tumors of the pancreas, biliary system, gallbladder, liver, small bowel, or colon, are provided. Methods include deploying a drug-eluting device having a film which includes a mixture of a degradable polymer and a chemotherapeutic drug, wherein the film has a thickness from about 2 μm to about 1000 μm, into a tissue site and releasing a therapeutically effective amount of the chemotherapeutic drug from the film to treat the tumor, wherein the release of the therapeutically effective amount of the drug from the film is controlled by in vivo degradation of the polymer at the tissue site.",MASSACHUSETTS INST TECHNOLOGY;;GEN HOSPITAL CORP,INDOLFI LAURA;;EDELMAN ELAZER R;;LANGER ROBERT S;;CLARK JEFFREY W;;TING DAVID T;;FERRONE CRISTINA ROSA ANNAMARIA;;LIGORIO MATTEO,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2014-04-18);;THE GENERAL HOSPITAL CORPORATION (2014-04-28),https://lens.org/157-818-238-425-485,Patent Application,yes,8,0,14,14,0,A61K47/34;;A61K9/0024;;A61K9/0034;;A61L31/16;;A61L2300/416;;A61L2300/604;;A61F2/915;;A61F2230/0021;;A61K9/7007;;A61K31/337;;A61F2002/041;;A61L31/10;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P35/00;;A61K9/7007;;A61K31/337;;A61F2002/041;;A61K47/34;;A61K9/0024;;A61K9/0034;;A61L31/16;;A61L2300/416;;A61L2300/604;;A61F2/915;;A61F2230/0021;;A61L31/10;;A61L31/148;;A61L2300/606;;A61L2420/06,A61L31/10;;A61K9/70;;A61K31/337;;A61L31/14;;A61L31/16,,0,0,,,,ACTIVE
2,CA,A1,CA 2944480 A1,072-884-722-116-194,2014-10-16,2014,CA 2944480 A,2014-04-10,US 201361810543 P;;US 2014/0033671 W,2013-04-10,LOCAL DRUG DELIVERY DEVICES AND METHODS FOR TREATING CANCER,"Drug-eluting devices and methods for the treatment of tumors of the pancreas, biliary system, gallbladder, liver, small bowel, or colon, are provided. Methods include deploying a drug-eluting device having a film which includes a mixture of a degradable polymer and a chemotherapeutic drug, wherein the film has a thickness from about 2 µm to about 1000 µm, into a tissue site and releasing a therapeutically effective amount of the chemotherapeutic drug from the film to treat the tumor, wherein the release of the therapeutically effective amount of the drug from the film is controlled by in vivo degradation of the polymer at the tissue site.",MASSACHUSETTS INST TECHNOLOGY;;MASSACHUSETTS GEN HOSPITAL,INDOLFI LAURA;;EDELMAN ELAZER R;;LANGER ROBERT S;;CLARK JEFFREY W;;TING DAVID T;;FERRONE CRISTINA ROSA ANNAMARIA;;LIGORIO MATTEO,,https://lens.org/072-884-722-116-194,Patent Application,no,0,0,14,14,0,A61K47/34;;A61K9/0024;;A61K9/0034;;A61L31/16;;A61L2300/416;;A61L2300/604;;A61F2/915;;A61F2230/0021;;A61K9/7007;;A61K31/337;;A61F2002/041;;A61L31/10;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P35/00;;A61K9/7007;;A61K31/337;;A61F2002/041;;A61K47/34;;A61K9/0024;;A61K9/0034;;A61L31/16;;A61L2300/416;;A61L2300/604;;A61F2/915;;A61F2230/0021;;A61L31/10;;A61L31/148;;A61L2300/606;;A61L2420/06,A61L31/10;;A61F2/04;;A61K9/70,,0,0,,,,ACTIVE
3,JP,A,JP 2019034962 A,164-842-112-446-946,2019-03-07,2019,JP 2018207608 A,2018-11-02,US 201361810543 P,2013-04-10,LOCAL DRUG DELIVERY DEVICES AND METHODS FOR TREATING CANCER,"To provide drug-eluting devices and methods for the treatment of tumors of the pancreas, biliary system, gallbladder, liver, small bowel, or colon.SOLUTION: The methods include: deploying in a tissue site a drug-eluting device having a film which includes a mixture of a degradable polymer and a chemotherapeutic drug, where the film has a thickness from about 2 μm to about 1000 μm; and releasing a therapeutically effective amount of the chemotherapeutic drug from the film to treat the tumor, where the release of the therapeutically effective amount of the drug from the film is controlled by in vivo degradation of the polymer at the tissue site.SELECTED DRAWING: Figure 15",MASSACHUSETTS INST TECHNOLOGY;;MASSACHUSETTS GEN HOSPITAL,LAURA INDOLFI;;ELAZER R EDELMAN;;ROBERT S LANGER;;JEFFREY W CLARK;;DAVID T TING;;CRISTINA ROSA ANNAMARIA FERRONE;;MATTEO LIGORIO,,https://lens.org/164-842-112-446-946,Patent Application,no,0,0,14,14,0,A61K47/34;;A61K9/0024;;A61K9/0034;;A61L31/16;;A61L2300/416;;A61L2300/604;;A61F2/915;;A61F2230/0021;;A61K9/7007;;A61K31/337;;A61F2002/041;;A61L31/10;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P35/00;;A61K9/7007;;A61K31/337;;A61F2002/041;;A61K47/34;;A61K9/0024;;A61K9/0034;;A61L31/16;;A61L2300/416;;A61L2300/604;;A61F2/915;;A61F2230/0021;;A61L31/10;;A61L31/148;;A61L2300/606;;A61L2420/06,A61K9/70;;A61K31/282;;A61K31/337;;A61K31/4745;;A61K31/513;;A61K31/7068;;A61K47/34;;A61L31/04;;A61L31/06;;A61L31/14;;A61L31/16;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P35/00,,0,0,,,,PENDING
4,EP,B1,EP 2983730 B1,078-980-199-921-161,2019-10-16,2019,EP 14727109 A,2014-04-10,US 201361810543 P;;US 2014/0033671 W,2013-04-10,LOCAL DRUG DELIVERY DEVICES AND METHODS FOR TREATING CANCER,,MASSACHUSETTS INST TECHNOLOGY;;MASSACHUSETTS GEN HOSPITAL,INDOLFI LAURA;;EDELMAN ELAZER R;;LANGER ROBERT S;;CLARK JEFFREY W;;TING DAVID T;;FERRONE CRISTINA ROSA ANNAMARIA;;LIGORIO MATTEO,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2019-05-29);;THE GENERAL HOSPITAL CORPORATION (2019-05-29),https://lens.org/078-980-199-921-161,Granted Patent,yes,3,0,14,14,0,A61K47/34;;A61K9/0024;;A61K9/0034;;A61L31/16;;A61L2300/416;;A61L2300/604;;A61F2/915;;A61F2230/0021;;A61K9/7007;;A61K31/337;;A61F2002/041;;A61L31/10;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P35/00;;A61K9/7007;;A61K31/337;;A61F2002/041;;A61K47/34;;A61K9/0024;;A61K9/0034;;A61L31/16;;A61L2300/416;;A61L2300/604;;A61F2/915;;A61F2230/0021;;A61L31/10;;A61L31/148;;A61L2300/606;;A61L2420/06,A61L31/16;;A61F2/915;;A61K9/00;;A61K31/337;;A61K47/34;;A61L31/10,,3,0,,,"FEI LU ET AL: ""Effects of amphiphilic PCLPEGPCL copolymer addition on 5-fluorouracil release from biodegradable PCL films for stent application"", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 419, no. 1, 14 July 2011 (2011-07-14) , pages 77-84, XP028306615, ISSN: 0378-5173, DOI: 10.1016/J.IJPHARM.2011.07.020 [retrieved on 2011-07-23];;RANGANATH S H ET AL: ""The use of submicron/nanoscale PLGA implants to deliver paclitaxel with enhanced pharmacokinetics and therapeutic efficacy in intracranial glioblastoma in mice"", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 31, no. 19, 1 July 2010 (2010-07-01), pages 5199-5207, XP027027485, ISSN: 0142-9612 [retrieved on 2010-04-23];;DATABASE WPI Week 201335 Thomson Scientific, London, GB; AN 2013-B03395 XP002728111, -& CN 102 727 944 A (SHANGHAI FIRST PEOPLES HOSPITAL) 17 October 2012 (2012-10-17)",ACTIVE
5,CA,C,CA 2944480 C,106-213-831-256-57X,2021-05-18,2021,CA 2944480 A,2014-04-10,US 201361810543 P;;US 2014/0033671 W,2013-04-10,LOCAL DRUG DELIVERY DEVICES AND METHODS FOR TREATING CANCER,"Drug-eluting devices and methods for the treatment of tumors of the pancreas, biliary system, gallbladder, liver, small bowel, or colon, are provided. Methods include deploying a drug-eluting device having a film which includes a mixture of a degradable polymer and a chemotherapeutic drug, wherein the film has a thickness from about 2 µm to about 1000 µm, into a tissue site and releasing a therapeutically effective amount of the chemotherapeutic drug from the film to treat the tumor, wherein the release of the therapeutically effective amount of the drug from the film is controlled by in vivo degradation of the polymer at the tissue site.",MASSACHUSETTS INST TECHNOLOGY;;MASSACHUSETTS GEN HOSPITAL,INDOLFI LAURA;;EDELMAN ELAZER R;;LANGER ROBERT S;;CLARK JEFFREY W;;TING DAVID T;;FERRONE CRISTINA ROSA ANNAMARIA;;LIGORIO MATTEO,,https://lens.org/106-213-831-256-57X,Granted Patent,no,0,0,14,14,0,A61K47/34;;A61K9/0024;;A61K9/0034;;A61L31/16;;A61L2300/416;;A61L2300/604;;A61F2/915;;A61F2230/0021;;A61K9/7007;;A61K31/337;;A61F2002/041;;A61L31/10;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P35/00;;A61K9/7007;;A61K31/337;;A61F2002/041;;A61K47/34;;A61K9/0024;;A61K9/0034;;A61L31/16;;A61L2300/416;;A61L2300/604;;A61F2/915;;A61F2230/0021;;A61L31/10;;A61L31/148;;A61L2300/606;;A61L2420/06,A61L31/16;;A61F2/915;;A61K9/70;;A61K47/34;;A61M31/00,,0,0,,,,ACTIVE
6,WO,A1,WO 2014/169137 A1,013-265-029-558-039,2014-10-16,2014,US 2014/0033671 W,2014-04-10,US 201361810543 P,2013-04-10,LOCAL DRUG DELIVERY DEVICES AND METHODS FOR TREATING CANCER,"Drug-eluting devices and methods for the treatment of tumors of the pancreas, biliary system, gallbladder, liver, small bowel, or colon, are provided. Methods include deploying a drug-eluting device having a film which includes a mixture of a degradable polymer and a chemotherapeutic drug, wherein the film has a thickness from about 2 µm to about 1000 µm, into a tissue site and releasing a therapeutically effective amount of the chemotherapeutic drug from the film to treat the tumor, wherein the release of the therapeutically effective amount of the drug from the film is controlled by in vivo degradation of the polymer at the tissue site.",MASSACHUSETTS INST TECHNOLOGY;;GEN HOSPITAL CORP,INDOLFI LAURA;;EDELMAN ELAZER R;;LANGER ROBERT S;;CLARK JEFFREY W;;TING DAVID T;;FERRONE CRISTINA ROSA ANNAMARIA;;LIGORIO MATTEO,,https://lens.org/013-265-029-558-039,Patent Application,yes,3,0,14,14,0,A61K47/34;;A61K9/0024;;A61K9/0034;;A61L31/16;;A61L2300/416;;A61L2300/604;;A61F2/915;;A61F2230/0021;;A61K9/7007;;A61K31/337;;A61F2002/041;;A61L31/10;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P35/00;;A61K9/7007;;A61K31/337;;A61F2002/041;;A61K47/34;;A61K9/0024;;A61K9/0034;;A61L31/16;;A61L2300/416;;A61L2300/604;;A61F2/915;;A61F2230/0021;;A61L31/10;;A61L31/148;;A61L2300/606;;A61L2420/06,A61L31/10;;A61F2/04;;A61K9/70;;A61K47/34,,5,4,013-857-253-817-129;;056-619-951-194-535;;006-227-262-955-574;;004-638-197-363-241,21803141;;10.1016/j.ijpharm.2011.07.020;;20350766;;10.1016/j.biomaterials.2010.03.002;;21561347;;10.1056/nejmoa1011923;;15729251;;10.1016/s0016-5107(04)02570-2,"FEI LU ET AL: ""Effects of amphiphilic PCLPEGPCL copolymer addition on 5-fluorouracil release from biodegradable PCL films for stent application"", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 419, no. 1, 14 July 2011 (2011-07-14), pages 77 - 84, XP028306615, ISSN: 0378-5173, [retrieved on 20110723], DOI: 10.1016/J.IJPHARM.2011.07.020;;RANGANATH S H ET AL: ""The use of submicron/nanoscale PLGA implants to deliver paclitaxel with enhanced pharmacokinetics and therapeutic efficacy in intracranial glioblastoma in mice"", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 31, no. 19, 1 July 2010 (2010-07-01), pages 5199 - 5207, XP027027485, ISSN: 0142-9612, [retrieved on 20100423];;DATABASE WPI Week 201335, Derwent World Patents Index; AN 2013-B03395, XP002728111;;CONROY, T. ET AL., NEW ENGLAND J. MEDICINE, vol. 364, 2011, pages 1817 - 25;;LEE ET AL.: ""The Effect on Porcine Bile Duct of a Metallic Stent Covered with a Paclitaxel-Incorporated Membrane"", GASTROINTEST. ENDOSC., vol. 61, no. 2, February 2005 (2005-02-01), pages 296 - 301",PENDING
7,US,B2,US 9301926 B2,103-583-220-757-673,2016-04-05,2016,US 201414250025 A,2014-04-10,US 201414250025 A;;US 201361810543 P,2013-04-10,Local drug delivery devices and methods for treating cancer,"Drug-eluting devices and methods for the treatment of tumors of the pancreas, biliary system, gallbladder, liver, small bowel, or colon, are provided. Methods include deploying a drug-eluting device having a film which includes a mixture of a degradable polymer and a chemotherapeutic drug, wherein the film has a thickness from about 2 μm to about 1000 μm, into a tissue site and releasing a therapeutically effective amount of the chemotherapeutic drug from the film to treat the tumor, wherein the release of the therapeutically effective amount of the drug from the film is controlled by in vivo degradation of the polymer at the tissue site.",MASSACHUSETTS INST TECHNOLOGY;;GEN HOSPITAL CORP,INDOLFI LAURA;;EDELMAN ELAZER R;;LANGER ROBERT S;;CLARK JEFFREY W;;TING DAVID T;;FERRONE CRISTINA ROSA ANNAMARIA;;LIGORIO MATTEO,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2014-04-18);;THE GENERAL HOSPITAL CORPORATION (2014-04-28),https://lens.org/103-583-220-757-673,Granted Patent,yes,18,20,14,14,0,A61K47/34;;A61K9/0024;;A61K9/0034;;A61L31/16;;A61L2300/416;;A61L2300/604;;A61F2/915;;A61F2230/0021;;A61K9/7007;;A61K31/337;;A61F2002/041;;A61L31/10;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P35/00;;A61K9/7007;;A61K31/337;;A61F2002/041;;A61K47/34;;A61K9/0024;;A61K9/0034;;A61L31/16;;A61L2300/416;;A61L2300/604;;A61F2/915;;A61F2230/0021;;A61L31/10;;A61L31/148;;A61L2300/606;;A61L2420/06,A61K9/70;;A61F2/04;;A61F2/915;;A61K9/00;;A61K31/337;;A61K47/34;;A61L31/10;;A61L31/16,,15,9,006-605-729-130-96X;;006-227-262-955-574;;068-207-018-585-429;;099-248-545-977-382;;113-365-504-464-802;;004-638-197-363-241;;014-915-200-292-567;;013-857-253-817-129;;056-619-951-194-535,10.1111/j.1440-1746.2011.06866.x;;21793905;;21561347;;10.1056/nejmoa1011923;;10.1002/jps.22066;;20091819;;10.2147/ceg.s34435;;23837001;;pmc3699027;;10.1007/s00270-002-0439-x;;12042995;;15729251;;10.1016/s0016-5107(04)02570-2;;10.1055/s-0032-1309881;;22752887;;21803141;;10.1016/j.ijpharm.2011.07.020;;20350766;;10.1016/j.biomaterials.2010.03.002,"Chung, M. J. et al., ""Safety evaluation of self-expanding metallic biliary stents eluting gemcitabine in a porcine model,"" Journal of Gastroenterology and Hepatology 27 (2012) 261-267.;;ClinicalTrials.gov, ""Patency and Safety of the Drug Eluting Covered Biliary Stent Comparing to the Common Covered Biliary Stent (MIRA-cover),"" (available at http://clinicaltrials.gov/ct2/show/study/NCT01512563) last updated Jan. 15, 2012.;;Conroy, T. et al., ""FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer,"" The New England Journal of Medicine, 364:1817-25 (2011).;;Guo, S.R. et al., ""In vivo evaluation of 5-fluorouracil-containing self-expandable nitinol stent in rabbits: Efficiency in long-term local drug delivery,"" J Pharm Sci. Jul. 2010; 99(7):3009-18.;;Hair, Clark D. et al., ""Future developments in biliary stenting,"" Clinical and Experimental Gastroenterology 2013:6 91-99.;;Han, Young-Min et al., ""Polyurethane-Covered Self-Expandable Nitinol Stent for Malignant Biliary Obstruction: Preliminary Results,"" Cardiovasc Intervent Radiol (2002) 25:381-382.;;Indolfi, Laura et al., Study-""Design of a Drug Eluting Stent for treatment of pancreatic malignancy,"" Abstract, Society for biomaterials (2013).;;Lee et al., ""The Effect on Porcine Bile Duct of a Metallic Stent Covered with a Paclitaxel-Incorporated Membrane,"" Gastrointest. Endosc. 61(2):296-301, Feb. 2005.;;Ligorio, Matteo et al., ""A novel drug-eluting platform for localized treatment of pancreatic cancer,"" Abstract, American Association for Cancer Research, Annual Meeting 2014, Apr. 5-9, 2014.;;Si, Jang et al., ""Porcine feasibility and safety of a new paclitaxel-eluting biliary stent with a Pluronic-containing membrane,"" Endoscopy 2012; 44:825-831.;;Taewoong Medical, Taewoong Niti-STM biliary stents (available at http://www.stent.net/new/sub.php?localNum=2&pageNum=1&subNum=1&subNum2=2) accessedOct. 23, 2013.;;Lu et al., ""Effects of Amphiphilic PCL-PEG-PCL Copolymer Addition on 5-Fluorouracil Release from Biodegradable PCL Films for Stent Application,"" International Journal of Pharmaceutics, 2011, 419:77-84.;;Ranganath, ""The Use of Submicron/Nanoscale PLGA Implants to Deliver Paclitaxel with Enhanced Pharmacokinetics and Therapeutic Efficacy in Intracranial Glioblastoma in Mice,"" Biomaterials, 2010, 31:5199-5207.;;Database WPI, week 201335; AN 2013-BC3395, CN 1027227944A, Oct. 17, 2012, XP00272811 (10 pages).;;PCT International Search Report and Written Opinion for PCT Application No. PCT/US2014/033671 mailed Aug. 12, 2014 (20 pages).",ACTIVE
8,ES,T3,ES 2762555 T3,196-445-307-657-307,2020-05-25,2020,ES 14727109 T,2014-04-10,US 201361810543 P;;US 2014/0033671 W,2013-04-10,Dispositivos y métodos de administración local de fármacos para el tratamiento del cáncer,"Un medicamento, que comprende paclitaxel, para su uso en el tratamiento de un tumor del páncreas, administrando localmente el paclitaxel a un sitio del tejido de un paciente, que necesita tratamiento, liberando una cantidad terapéuticamente efectiva del paclitaxel desde un dispositivo de liberación de fármaco implantado en el sitio del tejido, comprendiendo el dispositivo una película, que comprende una mezcla de un polímero degradable, que comprende poli(ácido láctico-co-glicólico) y el paclitaxel, en donde la película tiene un grosor de aproximadamente 2 μm a aproximadamente 1000 μm, en donde la liberación de la cantidad terapéuticamente efectiva del paclitaxel de la película se controla mediante la degradación in vivo del polímero en el sitio del tejido, y en donde la cantidad terapéuticamente efectiva es al menos 1 mg/día del paclitaxel.",MASSACHUSETTS INST TECHNOLOGY;;MASSACHUSETTS GEN HOSPITAL,INDOLFI LAURA;;EDELMAN ELAZER R;;LANGER ROBERT S;;CLARK JEFFREY W;;TING DAVID T;;FERRONE CRISTINA ROSA ANNAMARIA;;LIGORIO MATTEO,,https://lens.org/196-445-307-657-307,Granted Patent,no,0,0,14,14,0,A61K47/34;;A61K9/0024;;A61K9/0034;;A61L31/16;;A61L2300/416;;A61L2300/604;;A61F2/915;;A61F2230/0021;;A61K9/7007;;A61K31/337;;A61F2002/041;;A61L31/10;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P35/00;;A61K9/7007;;A61K31/337;;A61F2002/041;;A61K47/34;;A61K9/0024;;A61K9/0034;;A61L31/16;;A61L2300/416;;A61L2300/604;;A61F2/915;;A61F2230/0021;;A61L31/10;;A61L31/148;;A61L2300/606;;A61L2420/06,A61L31/16;;A61F2/915;;A61K9/00;;A61K31/337;;A61K47/34;;A61L31/10,,0,0,,,,ACTIVE
9,US,A1,US 2022/0054719 A1,005-313-831-442-563,2022-02-24,2022,US 202117520891 A,2021-11-08,US 202117520891 A;;US 201615055012 A;;US 201414250025 A;;US 201361810543 P,2013-04-10,Local Drug Delivery Devices and Methods for Treating Cancer,"Drug-eluting devices and methods for the treatment of tumors of the pancreas, biliary system, gallbladder, liver, small bowel, or colon, are provided. Methods include deploying a drug-eluting device having a film which includes a mixture of a degradable polymer and a chemotherapeutic drug, wherein the film has a thickness from about 2 μm to about 1000 μm, into a tissue site and releasing a therapeutically effective amount of the chemotherapeutic drug from the film to treat the tumor, wherein the release of the therapeutically effective amount of the drug from the film is controlled by in vivo degradation of the polymer at the tissue site.",MASSACHUSETTS INST TECHNOLOGY;;MASSACHUSETTS GEN HOSPITAL,INDOLFI LAURA;;EDELMAN ELAZER R;;LANGER ROBERT S;;CLARK JEFFREY W;;TING DAVID T;;FERRONE CRISTINA ROSA ANNAMARIA;;LIGORIO MATTEO,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2014-04-18);;THE GENERAL HOSPITAL CORPORATION (2014-04-28),https://lens.org/005-313-831-442-563,Patent Application,yes,3,0,14,14,0,A61K47/34;;A61K9/0024;;A61K9/0034;;A61L31/16;;A61L2300/416;;A61L2300/604;;A61F2/915;;A61F2230/0021;;A61K9/7007;;A61K31/337;;A61F2002/041;;A61L31/10;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P35/00;;A61K9/7007;;A61K31/337;;A61F2002/041;;A61K47/34;;A61K9/0024;;A61K9/0034;;A61L31/16;;A61L2300/416;;A61L2300/604;;A61F2/915;;A61F2230/0021;;A61L31/10;;A61L31/148;;A61L2300/606;;A61L2420/06,A61L31/10;;A61K9/00;;A61K9/70;;A61K31/337;;A61K47/34;;A61L31/14;;A61L31/16,,1,0,,,"(“flexible”, Merriam_Webster Dictionay, available at https://www.merriam-webster.com/dictionary/flexible, accessed on October 31, 2023",PENDING
10,US,B2,US 11167066 B2,184-258-854-446-139,2021-11-09,2021,US 201615055012 A,2016-02-26,US 201615055012 A;;US 201414250025 A;;US 201361810543 P,2013-04-10,Local drug delivery devices and methods for treating cancer,"Drug-eluting devices and methods for the treatment of tumors of the pancreas, biliary system, gallbladder, liver, small bowel, or colon, are provided. Methods include deploying a drug-eluting device having a film which includes a mixture of a degradable polymer and a chemotherapeutic drug, wherein the film has a thickness from about 2 μm to about 1000 μm, into a tissue site and releasing a therapeutically effective amount of the chemotherapeutic drug from the film to treat the tumor, wherein the release of the therapeutically effective amount of the drug from the film is controlled by in vivo degradation of the polymer at the tissue site.",MASSACHUSETTS INST TECHNOLOGY;;MASSACHUSETTS GEN HOSPITAL,INDOLFI LAURA;;EDELMAN ELAZER R;;LANGER ROBERT S;;CLARK JEFFREY W;;TING DAVID T;;FERRONE CRISTINA ROSA ANNAMARIA;;LIGORIO MATTEO,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2014-04-18);;THE GENERAL HOSPITAL CORPORATION (2014-04-28),https://lens.org/184-258-854-446-139,Granted Patent,yes,22,0,14,14,0,A61K47/34;;A61K9/0024;;A61K9/0034;;A61L31/16;;A61L2300/416;;A61L2300/604;;A61F2/915;;A61F2230/0021;;A61K9/7007;;A61K31/337;;A61F2002/041;;A61L31/10;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P35/00;;A61K9/7007;;A61K31/337;;A61F2002/041;;A61K47/34;;A61K9/0024;;A61K9/0034;;A61L31/16;;A61L2300/416;;A61L2300/604;;A61F2/915;;A61F2230/0021;;A61L31/10;;A61L31/148;;A61L2300/606;;A61L2420/06,A61K9/70;;A61F2/04;;A61F2/915;;A61K9/00;;A61K31/337;;A61K47/34;;A61L31/10;;A61L31/14;;A61L31/16,,18,12,047-220-770-835-54X;;013-857-253-817-129;;056-619-951-194-535;;006-605-729-130-96X;;006-227-262-955-574;;068-207-018-585-429;;099-248-545-977-382;;113-365-504-464-802;;004-638-197-363-241;;014-915-200-292-567;;010-222-855-393-775;;015-692-139-777-290,21640806;;10.1016/j.ijpharm.2011.05.049;;21803141;;10.1016/j.ijpharm.2011.07.020;;20350766;;10.1016/j.biomaterials.2010.03.002;;10.1111/j.1440-1746.2011.06866.x;;21793905;;21561347;;10.1056/nejmoa1011923;;10.1002/jps.22066;;20091819;;10.2147/ceg.s34435;;23837001;;pmc3699027;;10.1007/s00270-002-0439-x;;12042995;;15729251;;10.1016/s0016-5107(04)02570-2;;10.1055/s-0032-1309881;;22752887;;10.1016/j.jvs.2006.08.046;;17145446;;10.1007/s10620-012-2472-1;;23179148,"Fredenberg, S., et al., The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems—A review, International Journal of Pharmaceutics, vol. 415, Issues 1-2, Aug. 30, 2011, pp. 34-52.;;Lu et al., “Effects of Amphiphilic PCL-PEG-PCL Copolymer Addition on 5-Fluorouracil Release from Biodegradable PCL Films for Stent Application,” International Journal of Pharmaceutics, 2011, 419:77-84.;;Ranganath, “The Use of Submicron/Nanoscale PLGA Implants to Deliver Paclitaxel with Enhanced Pharmacokinetics and Therapeutic Efficacy in Intracranial Glioblastoma in Mice,” Biomaterials, 2010, 31:5199-5207.;;DITTERT J.: ""DER NEUE MOTOR MIT 1,4 L HUBRAUM FUER DEN VW GOLF."", MTZ - MOTORTECHNISCHE ZEITSCHRIFT, SPRINGER, vol. 52., no. 12., 1 December 1991 (1991-12-01), pages 616 - 620., XP000272811, ISSN: 0024-8525;;PCT International Search Report and Written Opinion for PCT Application No. PCT/US2014/033671 dated Aug. 12, 2014 (12 pages).;;Chung, M. J. et al., “Safety evaluation of self-expanding metallic biliary stents eluting gemcitabine in a porcine model,” Journal of Gastroenterology and Hepatology 27 (2012) 261-267.;;ClinicalTrials.gov, “Patency and Safety of the Drug Eluting Covered Biliary Stent Comparing to the Common Covered Biliary Stent (MIRA-cover),” (available at http://clinicaltrials.gov/ct2/show/study/NCT01512563) last updated Jan. 15, 2012.;;Conroy, T. et al., “Folfirinox versus Gemcitabine for Metastatic Pancreatic Cancer,” The New England Journal of Medicine, 364:1817-25 (2011).;;Guo, S.R. et al., “In vivo evaluation of 5-fluorouracil-containing self-expandable nitinol stent in rabbits: Efficiency in long-term local drug delivery,” J Pharm Sci. Jul. 2010; 99(7):3009-18.;;Hair, Clark D. et al., “Future developments in biliary stenting,” Clinical and Experimental Gastroenterology 2013:691-99.;;Han, Young-Min et al., “Polyurethane-Covered Self-Expandable Nitinol Stent for Malignant Biliary Obstruction: Preliminary Results,” Cardiovasc Intervent Radiol (2002) 25:381-382.;;Indolfi, Laura et al., Study—“Design of a Drug Eluting Stent for treatment of pancreatic malignancy,” Abstract, Society for biomaterials (2013).;;Lee et al., “The Effect on Porcine Bile Duct of a Metallic Stent Covered with a Paclitaxel-Incorporated Membrane,” Gastrointest. Endosc. 61(2):296-301, Feb. 2005.;;Ligorio, Matteo et al., “A novel drug-eluting platform for localized treatment of pancreatic cancer,” Abstract, American Association for Cancer Research, Annual Meeting 2014, Apr. 5-9, 2014.;;Si, Jang et al., “Porcine feasibility and safety of a new paclitaxel-eluting biliary stent with a Pluronic-containing membrane,” Endoscopy 2012; 44:825-831.;;Taewoong Medical, Taewoong Niti-STM biliary stents (available at http://www.stent.net/new/sub.php? localNum=2&pageNum=1&subNum=1&subNum2=2) accessed Oct. 23, 2013.;;Caves et al., “The Evolving Impact of Microfabrication and Nanotechnology on Stent Design,” Journal of Vascular Surgery, 2006, pp. 1363-1368.;;Jang et al., “Efficacy of a Metallic Stent Covered with a Paclitaxel-Incorporated Membrane Versus a Covered Metal Stent for Malignant Biliary Obstruction: A Prospective Comparative Study,” Dig. Dis. Sci., 2013, 58:865-871.",ACTIVE
11,US,A1,US 2014/0308336 A1,073-517-070-810-35X,2014-10-16,2014,US 201414250025 A,2014-04-10,US 201414250025 A;;US 201361810543 P,2013-04-10,LOCAL DRUG DELIVERY DEVICES AND METHODS FOR TREATING CANCER,"Drug-eluting devices and methods for the treatment of tumors of the pancreas, biliary system, gallbladder, liver, small bowel, or colon, are provided. Methods include deploying a drug-eluting device having a film which includes a mixture of a degradable polymer and a chemotherapeutic drug, wherein the film has a thickness from about 2 μm to about 1000 μm, into a tissue site and releasing a therapeutically effective amount of the chemotherapeutic drug from the film to treat the tumor, wherein the release of the therapeutically effective amount of the drug from the film is controlled by in vivo degradation of the polymer at the tissue site.",MASSACHUSETTS INST TECHNOLOGY;;GEN HOSPITAL CORP,INDOLFI LAURA;;EDELMAN ELAZER R;;LANGER ROBERT S;;CLARK JEFFREY W;;TING DAVID T;;FERRONE CRISTINA ROSA ANNAMARIA;;LIGORIO MATTEO,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2014-04-18);;THE GENERAL HOSPITAL CORPORATION (2014-04-28),https://lens.org/073-517-070-810-35X,Patent Application,yes,3,13,14,14,0,A61K47/34;;A61K9/0024;;A61K9/0034;;A61L31/16;;A61L2300/416;;A61L2300/604;;A61F2/915;;A61F2230/0021;;A61K9/7007;;A61K31/337;;A61F2002/041;;A61L31/10;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P35/00;;A61K9/7007;;A61K31/337;;A61F2002/041;;A61K47/34;;A61K9/0024;;A61K9/0034;;A61L31/16;;A61L2300/416;;A61L2300/604;;A61F2/915;;A61F2230/0021;;A61L31/10;;A61L31/148;;A61L2300/606;;A61L2420/06,A61K9/70;;A61F2/04;;A61K31/337,424/444;;514/449;;514/49;;514/274;;514/492;;514/283;;623/23.7,0,0,,,,ACTIVE
12,EP,A1,EP 2983730 A1,163-455-113-332-768,2016-02-17,2016,EP 14727109 A,2014-04-10,US 201361810543 P;;US 2014/0033671 W,2013-04-10,LOCAL DRUG DELIVERY DEVICES AND METHODS FOR TREATING CANCER,,MASSACHUSETTS INST TECHNOLOGY;;GEN HOSPITAL CORP,INDOLFI LAURA;;EDELMAN ELAZER R;;LANGER ROBERT S;;CLARK JEFFREY W;;TING DAVID T;;FERRONE CRISTINA ROSA ANNAMARIA;;LIGORIO MATTEO,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2019-05-29);;THE GENERAL HOSPITAL CORPORATION (2019-05-29),https://lens.org/163-455-113-332-768,Patent Application,yes,0,0,14,14,0,A61K47/34;;A61K9/0024;;A61K9/0034;;A61L31/16;;A61L2300/416;;A61L2300/604;;A61F2/915;;A61F2230/0021;;A61K9/7007;;A61K31/337;;A61F2002/041;;A61L31/10;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P35/00;;A61K9/7007;;A61K31/337;;A61F2002/041;;A61K47/34;;A61K9/0024;;A61K9/0034;;A61L31/16;;A61L2300/416;;A61L2300/604;;A61F2/915;;A61F2230/0021;;A61L31/10;;A61L31/148;;A61L2300/606;;A61L2420/06,A61L31/10;;A61F2/04;;A61K9/70;;A61K47/34,,0,0,,,,ACTIVE
